全文获取类型
收费全文 | 185篇 |
免费 | 7篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 5篇 |
妇产科学 | 8篇 |
基础医学 | 22篇 |
口腔科学 | 5篇 |
临床医学 | 9篇 |
内科学 | 37篇 |
皮肤病学 | 5篇 |
神经病学 | 11篇 |
特种医学 | 12篇 |
外科学 | 28篇 |
预防医学 | 7篇 |
药学 | 29篇 |
肿瘤学 | 10篇 |
出版年
2022年 | 5篇 |
2021年 | 7篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2016年 | 7篇 |
2015年 | 3篇 |
2014年 | 10篇 |
2013年 | 8篇 |
2012年 | 10篇 |
2011年 | 16篇 |
2010年 | 11篇 |
2009年 | 9篇 |
2008年 | 17篇 |
2007年 | 18篇 |
2006年 | 18篇 |
2005年 | 9篇 |
2004年 | 6篇 |
2003年 | 6篇 |
2002年 | 3篇 |
2001年 | 5篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1992年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有193条查询结果,搜索用时 31 毫秒
11.
Anopheles gambiae laminin interacts with the P25 surface protein of Plasmodium berghei ookinetes 总被引:2,自引:0,他引:2
Vlachou D Lycett G Sidén-Kiamos I Blass C Sinden RE Louis C 《Molecular and biochemical parasitology》2001,112(2):229-237
Laminin is a major constituent of the basal lamina surrounding the midgut of the malaria vectors that has been implicated in the development of the Plasmodium oocyst. In this report we describe the cloning of the Anopheles gambiae gene encoding the laminin gamma 1 polypeptide and follow its expression during mosquito development. To further investigate the putative role of laminin in the transmission of the malaria parasite we studied the potential binding of the P25 surface protein of Plasmodium berghei using a yeast two-hybrid system. Heterodimer formation was observed and does not require any additional protein factors since purified fusion proteins can also bind each other in vitro. Laminin gamma 1 also interacts with the paralogue of P25, namely P28, albeit more weakly, possibly explaining why the two parasite proteins can substitute for each other in deletion mutants. This represents the first direct evidence for molecular interactions between a surface protein of the Plasmodium parasite with an Anopheles protein; the strong interplay between laminin gamma 1 and P25 suggests that this pair of proteins may function as a receptor/ligand complex regulating parasite development in the mosquito vector. 相似文献
12.
Ossifying fibroma of the temporal bone 总被引:1,自引:0,他引:1
Vlachou S Terzakis G Doundoulakis G Barbati C Papazoglou G 《The Journal of laryngology and otology》2001,115(8):654-656
A rare case of ossifying fibroma of the temporal bone is presented. Fibro-osseous lesions are benign neoplasms but may show an aggressive behaviour when invading important anatomical structures. The lack of experience in the treatment of those tumours is reflected in the small relative literature. The purpose of this paper is to contribute to the few cases already reported. 相似文献
13.
I Papassotiriou J Traeger-Synodinos C Vlachou M Karagiorga A Metaxotou E Kanavakis A Stamoulakatou 《Hemoglobin》1999,23(3):203-211
The Bio-Rad Variant Hemoglobin testing system is an automated high performance liquid chromatography analyzer marketed with a beta-thalassemia short program to quantify Hbs F and A2, and assist in detecting Hbs A, S, D, C, and E. Although the two hemoglobins present in Hb H disease, Hb Bart's and Hb H, are separated by the system, they are not quantitated. In this study we modified the beta-thalassemia short program in order to facilitate quantitation of Hb Bart's and Hb H. Blood samples from 60 patients with Hb H disease, with various underlying genotypes, were studied. Analyses were performed on the day of blood collection or on hemolysates stored at -80 degrees C in cyanide or carbomonoxy forms. The mean sum of Hb Bart's and Hb H levels in all patients was found to be 12% (range 1.8-35%). Patients with nondeletional mutations (or association of alpha(0) deletion and nondeletional mutations) had notably higher Hb Bart's and Hb H levels when compared to patients with deletional genotypes. 相似文献
14.
Constant advances in gene mapping technology have allowed research to focus from rare monogenic disorders on common complex diseases involving multiple susceptibility genes-environment interactions. Gestational diabetes mellitus (GDM) is a heterogeneous pathogenic condition affecting 2-5% of all pregnant women during pregnancy. GDM is considered to result when genetic predisposition is triggered by increased insulin resistance during pregnancy leading to what seems to be one of the primary characteristics of GDM, the pancreatic b-cell impairment. Genetic predisposition to GDM has been suggested given the occurrence of the disease within family members. Furthermore, GDM is reported to be often present in women with maturity onset diabetes of the young (MODY) gene mutations. In addition, candidate susceptibility gene variants have been suggested to increase the risk of GDM. These genes include glucokinase (GCK), HLA antigens, insulin receptor (INSR), insulin-like growth factor-2 (IGF2), HNF4A, insulin gene (INS-VNTR), plasminogen activator inhibitor 1 (PAI-1), potassium inwardly rectifying channel subfamily J, member 11 (KCNJ11), hepatocyte nuclear factor-4a (HNF4A). Identification of the possible underlying genetic factors of GDM would eventually enrich our knowledge on the pathophysiologic mechanism of the disease and contribute to the individualization of both prevention and treatment of complications for the mother and fetus. However, so far, little is known about the genetic basis of GDM and its potential clinical significance. This review focuses on possible gestational diabetes mellitus susceptibility genes and their association with the disease incidence and severity as well as the pregnancy outcome and the response to treatment. 相似文献
15.
16.
Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor 下载免费PDF全文
Barabutis N Tsellou E Schally AV Kouloheri S Kalofoutis A Kiaris H 《Proceedings of the National Academy of Sciences of the United States of America》2007,104(13):5575-5579
Recent evidence indicates that growth hormone-releasing hormone (GHRH) functions as an autocrine/paracrine growth factor for various human cancers. A splice variant (SV) of the full-length receptor for GHRH (GHRHR) is widely expressed in various primary human cancers and established cancer cell lines and appears to mediate the proliferative effects of GHRH. To investigate in greater detail the role of SV1 in tumorigenesis, we have expressed the full-length GHRHR and its SV1 in MCF-7 human breast cancer cells that do not possess either GHRHR or SV1. In accordance with previous findings, the expression of both GHRHR and SV1 restored the sensitivity to GHRH-induced stimulation of cell proliferation, with SV1 being more potent than the GHRHR. Furthermore, MCF-7 cells transfected with SV1 proliferated more quickly than the controls, even in the absence of exogenously added GHRH, suggesting the existence of intrinsic, ligand-independent activity of SV1 after its transfection. In agreement with the stimulation of cell proliferation, the levels of proliferation markers cyclin D1, cyclin E, and proliferating cell nuclear antigen were elevated in MCF-7 cells treated with GHRH, cultured in both serum-free and serum-containing media. In addition, SV1 caused a considerable stimulation of the ability of MCF-7 cells to grow in semisolid medium, an assay considered diagnostic for cell transformation. Collectively, our findings show that the expression of SV1 confers oncogenic activity and provide further evidence that GHRH operates as a growth factor in breast cancer and probably other cancers as well. 相似文献
17.
Twelve patients (17 feet) with progressive neuromuscular planovalgus foot deformity underwent an extra-articular subtalar arthrodesis with the combined Batchelor-Grice procedure. All patients were ambulant and received conservative treatment with braces and special orthopaedic shoes before the operation. Postoperatively the feet were immobilized in short leg casts for 6 weeks. Evaluation was based on the appearance of the feet, the clinical symptoms and radiographic measurements. Solid fusion and sustained correction took place in all feet. Foot appearance and mobility of the patients were improved, whereas preoperative complaints were reduced. The gap at the graft donor site was bridged with new bone in all cases. 相似文献
18.
Panagiotis Mallis Efstathios Michalopoulos Amalia Dinou Maria Spyropoulou Vlachou Efrosyni Panagouli Aggeliki Papapanagiotou Eva Kassi Catherine Stavropoulos Giokas 《Human immunology》2018,79(12):855-860
Worldwide, there is a great need of small diameter vascular grafts that can be used in human disorders such as cardiovascular and peripheral vascular disease. Until now, severe adverse reactions are caused from the use of synthetic or animal derived grafts, while the use of autologous vessels is restricted only in a small number of patients. The limited availability of the vessels might be resolved by the use of HLA-matched vascular grafts utilizing the decellularized human umbilical arteries. In this study, human umbilical arteries were decellularized and then repopulated with Mesenchymal Stem Cells. The HLA-genotype of the repopulated grafts, analyzed by Next Generation Sequencing technology, indicated their successful production. The HLA-matched vascular grafts could be generated efficiently and might be used in personalized medicine. 相似文献
19.
Efstathios Kastritis Maria Roussou Maria Gavriatopoulou Magdalini Migkou Despina Kalapanida Constantinos Pamboucas Elisavet Kaldara Argyrios Ntalianis Erasmia Psimenou Savvas T. Toumanidis Anna Tasidou Evangelos Terpos Meletios A. Dimopoulos 《American journal of hematology》2015,90(4):E60-E65
Bortezomib and lenalidomide are increasingly used in patients with AL amyloidosis, but long term data on their use as primary therapy in AL amyloidosis are lacking while early mortality remains significant. Thus, we analyzed the long term outcomes of 85 consecutive unselected patients, which received primary therapy with bortezomib or lenalidomide and we prospectively evaluated a risk adapted strategy based on bortezomib/dexamethasone to reduce early mortality. Twenty‐six patients received full‐dose bortezomib/dexamethasone, 36 patients lenalidomide with oral cyclophosphamide and low‐dose dexamethasone and 23 patients received bortezomib/dexamethasone at a dose and schedule adjusted to the risk of early death. On intent to treat, 67% of patients achieved a hematologic response (24% hemCRs) and 34% an organ response; both were more frequent with bortezomib. An early death occurred in 20%: in 36% of those treated with full‐dose bortezomib/dexamethasone, in 22% of lenalidomide‐treated patients but only in 4.5% of patients treated with risk‐adapted bortezomib/dexamethasone. Activity of full vs. adjusted dose bortezomib/dexamethasone was similar; twice weekly vs. weekly administration of bortezomib also had similar activity. After a median follow up of 57 months, median survival is 47 months and is similar for patients treated with bortezomib vs. lenalidomide‐based regimens. However, risk adjusted‐bortezomib/dexamethasone was associated with improved 1‐year survival vs. full‐dose bortezomib/dexamethasone or lenalidomide‐based therapy (81% vs. 56% vs. 53%, respectively). In conclusion, risk‐adapted bortezomib/dexamethasone may reduce early mortality and preserve activity while long term follow up indicates that remissions obtained with lenalidomide or bortezomib may be durable, even without consolidation with alkylators.Am. J. Hematol. 90:E60–E65, 2015. © 2015 Wiley Periodicals, Inc. 相似文献
20.
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
Irene Lambrinoudaki Sophia Vlachou Fotini Galapi Dimitra Papadimitriou K Papadias 《Clinical Interventions in Aging》2008,3(3):445-451
Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw. 相似文献